Publications by authors named "C Nicotra"
Background Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic urothelial carcinoma (mUC) is a dangerous cancer with few treatment options, and its genetic makeup is not fully understood unlike non-metastatic urothelial carcinoma (UC).
- A study analyzing genetic data from 111 mUC biopsies found that common genetic changes are similar to those seen in primary UC and highlighted mutational signatures related to APOBEC, platinum sensitivity, and homologous recombination deficiency.
- The research revealed that a significant portion of mUC patients have potential therapeutic targets, with the most common being FGFR3, ERBB2, TSC1, and PIK3CA, and noted that certain genes like NECTIN4 and TACSTD2 are consistently highly expressed across different
Article Synopsis
- - The MATCH-R trial aimed to analyze the resistance mechanisms to cancer treatments by studying fresh tumor biopsies from metastatic patients, covering data collected from 2015 to 2022.
- - Out of 1,120 biopsies from patients primarily with lung, digestive, and prostate cancers, 30.9% revealed targetable genomic alterations, with EGFR being the most common altered gene.
- - Among patients with resistance mechanisms, 45% had treatments tailored based on identified mechanisms, resulting in an average of 11 months of additional clinical benefit.
Background & Aims: Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims to evaluate whether PDOs can be implemented in clinical practice to benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC).
View Article and Find Full Text PDF